Infectious Disease

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

IDWeek 2023: Infectious disease specialist, Gopi Patel, MD, discusses universal masking in health care settings.

Clinicians must remember the point of vaccines was not to prevent infection, but to decrease severity of illness, says infectious disease specialist Gopi Patel, MD.

Gopi Patel, MD, emphasizes the importance of promoting vaccination and infection prevention measures among fellow clinicians, as well as patients, this season.

Your daily dose of the clinical news you may have missed.

IDWeek 2023 chair Yun points to climate change and other human-driven devastation of the biosphere as the global threats that will cause disease at local levels.

IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.

IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,

IDWeek 2023. Results highlight potential impact of influenza vaccination in reducing CV, respiratory, and other complications in adults aged ≥65 years with underlying chronic conditions.

The phase 2 study found that nAB responses against epithelial cell infection were strong after each mRNA-1647 dose and sustained through 12 months.

A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.

IDWeek 2023. The study identified disparities in coverage related to age, race, ethnicity, household income, insurance status, and prior influenza vaccination.

IDWeek 2023. New data shows non-Hispanic Black patients had a 13% lower likelihood of getting the influenza vaccine compared to non-Hispanic White patients.

A modeling study projected an annual reduction of nearly 25 000 infant hospitalizations and 46 000 ED encounters following maternal vaccination against RSV.

Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.

The study found that measles antibody levels during 2 long-term follow-ups fell lower than those observed before receipt of the third MMR dose.

The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.

The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.

Researchers say findings demonstrate the capacity to use an existing influenza vaccine effectiveness network to study a large immunocompromised population.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.

IDWeek 2023: Adolescents expressed a preference for a combination vaccine covering serogroups A, B, C, W, Y of invasive meningococcal disease, reported researchers.

COVID-19, influenza, and RSV will be the topics of a different types of sessions examining the history, new diagnostics, prevention, and future treatments during IDWeek 2023.

Findings underscore the persistence of disparities in meningococcal vaccination coverage in the US, particularly for vaccination against serogroup B.

IDWeek 2023: Leading physician scientists will headline plenary sessions and named lectureships on topics ranging from antibiotic stewardship to artificial intelligence.

Your daily dose of the clinical news you may have missed.

IDWeek 2023: Imagine an intriguing hot topic in infectious disease and you'll find a session or 2 where you can learn more and then choose the next topic, rinse, and repeat.

A 2-question quiz on the ACIP's recommendations on the new COVID-19 monovalent vaccines that provide protection from currently circulating strains.

The Novavax COVID-19 vaccine is refreshed with 2023-2024 formula targeting the XBB.1.5 strain.